Spondyloarthritis & psoriatic arthritis
Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: a post hoc analysis of the EXCEED study
Authors' conclusion
Secukinumab and adalimumab showed similar efficacy, including time to resolution, with respect to resolution of enthesitis.
Study context
- Population
- Patients with PsA in the EXCEED study, grouped by presence or absence of baseline enthesitis (Leeds Enthesitis Index (LEI) and SPARCC)
- Comparison
- Secukinumab 300 mg vs adalimumab 40 mg
- Primary endpoint
- Enthesitis resolution (LEI/SPARCC = 0)
- Follow-up
- Weeks 24 and 52
Methodological detailsnon-responder imputation, Kaplan-Meier analysis, as-observed data
- Non-responder imputation
- Kaplan-Meier analysis
- As-observed data
Primary result
As reported in the abstract
Resolution of enthesitis, LEI/SPARCC · week 24
Resolution of enthesitis, LEI/SPARCC · week 24 Secukinumab 49.6%/45.8% · Adalimumab 43.6%/43.5%
LEI
SPARCC
Further findings
Resolution of enthesitis, LEI/SPARCC · week 52 · non-responder imputation Secukinumab 60.7%/53.2% · Adalimumab 55.3%/51.4%
LEI
SPARCC
Resolution of enthesitis, LEI/SPARCC · week 52
- Similar proportions achieved resolution of LEI and SPARCC
Baseline enthesitis prevalence
- Enthesitis by LEI
- 498 of 851 patients (58.5%)
- Enthesitis by SPARCC
- 632 of 853 patients (74.1%)
Mean time to enthesitis resolution
- Comparable mean time to enthesitis resolution
- Kaplan-Meier analysis
Improvement at individual enthesitis sites
- Improvements were similar for both drugs at individual enthesitis sites
Quality of life · week 52
- Resolution of enthesitis associated with improvements in quality of life
Original publication
Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: a post hoc analysis of the EXCEED study. Rheumatology (Oxford). Published 25 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →